ASD are characterized by pervasive impairment in language and communication, social reciprocity, and having restricted interests or stereotyped behaviors^[@R1]^. Several new candidate loci for ASD have recently been identified using genome-wide approaches that discover individually rare events of major effect^[@R2]^. A number of genetic syndromes with features of the ASD phenotype, collectively referred to as syndromic autism, have also been described^[@R4]^. Despite this progress, the genetic basis for the vast majority of ASD cases remains unknown. Several observations support the hypothesis that the genetic basis for ASD in sporadic cases may differ from that of families with multiple affected individuals, with the former more likely to result from *de novo* mutation events rather than inherited variants^[@R1],[@R5]--[@R7]^. In this study, we sequenced the protein-coding regions of the genome (the exome)^[@R8]^ to test the hypothesis that *de novo* protein-altering mutations substantially contribute to the genetic basis of sporadic ASD. In contrast with array-based analysis of large *de novo* copy number variants (CNVs), this approach has greater potential to implicate single genes in ASD.

We selected 20 trios with idiopathic ASD, each consistent with sporadic ASD based on clinical evaluations ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}), pedigree structure, familial phenotypic evaluation, family history, and/or elevated parental age. Each family was initially screened by array comparative genomic hybridization (CGH) using a customized microarray^[@R9]^. We identified no large (\>250 kbp) *de novo* CNVs but did identify a maternally inherited deletion (\~350 kbp) at 15q11.2 in one family ([Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}). This deletion has been associated with increased risk for epilepsy^[@R10]^ and schizophrenia^[@R11],[@R12]^ but has not been considered as causal for autism.

Similar to Vissers and colleagues^[@R13]^, who reported exome sequencing on 10 parent-child trios with sporadic cases of moderate to severe intellectual disability (ID), we performed exome sequencing on each of the 60 individuals separately, by subjecting whole-blood derived genomic DNA to in-solution hybrid capture and Illumina sequencing (**Methods**). We obtained sufficient coverage to call variants for \~90% of the primary target (26.4 Mb) ([Table 1](#T1){ref-type="table"}). Genotype concordance with SNP microarray data was high (99.7%) ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}) and on average 96% of proband variant sites were also called in both parents ([Supplementary Table 3](#SD1){ref-type="supplementary-material"}). Given the expected rarity of true *de novo* events in the targeted exome (\<1/trio) ([Supplementary Table 4](#SD1){ref-type="supplementary-material"})^[@R14]^, we reasoned that most apparently *de novo* variants would result from undercalling in parents or systematic false positive calls in the proband. We therefore filtered variants previously observed in dbSNP, 1000 Genomes Pilot Project data^[@R15]^, and 1490 other exomes sequenced at the University of Washington ([Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}). We performed Sanger sequencing on the remaining *de novo* candidates (\<5/trio), validating 18 events within coding sequence and three additional events mapping to 3′ untranslated regions ([Table 2](#T2){ref-type="table"}). A list of predicted variant sites within these genes from the 1000 Genomes Pilot Project data^[@R15]^ is provided for comparison ([Supplementary Table 5](#SD1){ref-type="supplementary-material"}).

We observed subtle differences with respect to mutation rate and characteristics when compared to Vissers and colleagues^[@R13]^ ([Supplementary Note](#SD1){ref-type="supplementary-material"}). The overall protein-coding *de novo* rate (0.9 events/trio) was slightly higher than expected^[@R14]^ (0.59 events/trio), suggesting that we are identifying the majority of *de novo* events in these trios ([Supplementary Table 4](#SD1){ref-type="supplementary-material"}). The transition to transversion ratio was highly skewed (18:2), with eight transitions mapping to hypermutable CpG dinucleotides^[@R14]^. The proportion of synonymous events was higher than expected based on a neutral model and may reflect selection against embryonic lethal nonsynonymous variants. We successfully determined the parent of origin for seven events, six of which occurred on the paternal haplotype ([Table 2](#T2){ref-type="table"}). Notably, the eight probands with two or more validated *de novo* events corresponded to families with higher parental age (Mann--Whitney U, Combined Age, One-Sided P\<0.004).

Eleven of the 18 coding *de novo* events are predicted to alter protein function. Each of these mutations occurred at a different gene, precluding a statistical assessment for any specific locus despite their deleterious nature (e.g. PolyPhen-2^[@R16]^). We assessed whether proband *de novo* mutations were enriched in the aggregate for disruptive events by considering two independent quantitative measures: the nature of the amino-acid replacement (Grantham matrix score^[@R17]^) and the degree of nucleotide-level evolutionary conservation (Genomic Evolutionary Rate Profiling (GERP)^[@R18],[@R19]^) ([Fig. 1a,b](#F1){ref-type="fig"}). For comparison, we sequenced 20 exomes from unrelated ethnically matched controls (HapMap) and applied the same filters to identify coding-sequence mutations that were common or private to each of the samples. These control DNA were isolated from immortalized lymphoblasts; however, the counts of private variants in the cases and controls were highly similar suggesting that suggesting that the contribution of novel somatic events is likely minimal ([Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}).

We determined by simulation the expected mean GERP and Grantham distributions for 10 randomly selected common or private control single nucleotide variants (SNVs) (**Methods**). When we compared the observed means of the 10 *de novo* protein-altering ASD proband variants to the distribution of common control SNVs ([Fig. 1a](#F1){ref-type="fig"}), they corresponded to more highly conserved (GERP: p\<0.001) and disruptive amino acid mutations (Grantham: p=0.015). If we limited the analysis to the private control SNVs, which serve as a proxy for evolutionarily young mutation events ([Fig. 1b](#F1){ref-type="fig"}), we again found the *de novo* events were at the right tail of these distributions. Only the mean GERP score, however, remained significant (GERP: p=0.02, Grantham: p=0.115). In total, these results suggest that these *de novo* mutation sites are subjected to stronger selection and likely to have functional impact.

We identified a subset of trios (4/20) with disruptive *de novo* mutations that are potentially causative, including genes previously associated with autism, ID, and epilepsy ([Table 2](#T2){ref-type="table"} and [Supplementary Note](#SD1){ref-type="supplementary-material"}). We examined the available clinical data for each of these four families and found they were among the most severely affected individuals in our study based on intelligence quotient (IQ) measures and on calibrated severity score^[@R20]^ (CSS), which is largely independent from IQ and focuses specifically on autistic features with a score of 10 being most severe ([Fig. 1c,d](#F1){ref-type="fig"}). For example, in proband 12681 we identified a single-base substitution (IVS9-2A\>G, CCDS8662.1) at the canonical 3′ splice site of exon 10 in *Glutamate receptor, ionotropic, N-methyl D-aspartate 2B* (*GRIN2B*) ([Supplementary Fig. 4a,b](#SD1){ref-type="supplementary-material"}). She is severely affected (CSS 9), with evidence of early onset, possible regression, and comorbid for mild ID. Expression and association studies have suggested that glutamatergic neurotransmission may play a role in ASD^[@R4]^. Recently, Endele and colleagues^[@R21]^ described *GRIN2A* and *GRIN2B* as sites of recurrent *de novo* mutations in individuals with mild to moderate ID and/or epilepsy suggesting variable expressivity. Our data suggest that *de novo* mutations in *GRIN2B* may also lead to an ASD presentation.

Proband 12499 has a missense variant (p.P1894L, CCDS33316.1) predicted to be functionally deleterious and at a highly conserved position in *Sodium channel, voltage-gated, type I, alpha subunit* (*SCN1A*) ([Supplementary Fig. 4c](#SD1){ref-type="supplementary-material"}). He is severely affected (CSS 8) with evidence of early onset, possible regression, language delay, a diagnosis of epilepsy and mild ID. *SCN1A* was previously associated with epilepsy and suggested as an ASD candidate^[@R22],[@R23]^, although limited screening has been conducted in idiopathic ASD. Hundreds of disease-associated mutations have been described in epilepsy and typically patients with *de novo* events show more severe phenotypes^[@R24]^. The proband also carries the maternally inherited 15q11.2 deletion increasing the risk for epilepsy^[@R10]^.

Proband 11666 has a missense variant (p.D399G, CCDS6938.1) predicted to be functionally deleterious and at a highly conserved position within the second laminin-type epidermal growth factor-like domain of *Laminin, gamma 3* (*LAMC3*) ([Supplementary Fig. 4d](#SD1){ref-type="supplementary-material"}). He is severely affected (CSS 10) with evidence of early onset and moderate ID. *LAMC3* is not known to be involved in neuronal development; however, human microarray data have shown expression in many areas of the cortex and limbic system^[@R25]^. Additional study is warranted since laminins have structural similarities to the neurexin and contactin-associated families of proteins, both of which have been associated with ASD^[@R2]^.

The fourth example of a potentially causative mutation is a single-base insertion in *Forkhead box P1* (*FOXP1*), introducing a frameshift and premature stop codon (p.A339SfsX4, CCDS2914.1) in proband 12817 ([Fig. 1e](#F1){ref-type="fig"}). He is severely affected (CSS 8) with evidence for regression, language delay, and comorbidity for moderate ID and nonfebrile seizures. Recently, rare occurrences of large *de novo* deletions and a nonsense variant disrupting *FOXP1* were reported in individuals with mild to moderate ID and language defects, with or without ASD features^[@R26],[@R27]^. *FOXP1* encodes a member of the forkhead-box family of transcription factors and is closely related to *FOXP2,* a gene implicated in rare monogenic forms of speech and language disorder^[@R28]--[@R31]^. Functional evidence of heterodimer formation and overlapping neural expression patterns suggests that FOXP1 and FOXP2 can co-regulate gene expression in the brain^[@R32],[@R33]^. We assessed relative levels of the mutant transcript in proband derived lymphoblasts finding strong evidence for nonsense-mediated decay (NMD) ([Supplementary Fig. 5a](#SD1){ref-type="supplementary-material"}). HEK293T cell-based functional assays further demonstrated that, if translated, the protein would be truncated and mislocalized from the nucleus to the cytoplasm---similar to results obtained with FOXP2 mutations^[@R31]^ ([Supplementary Fig. 5b,c](#SD1){ref-type="supplementary-material"}).

Remarkably, in addition to the *FOXP1* mutation, proband 12817 also carried an inherited missense variant (p.H275A, CCDS5889.1) in *Contactin associated protein-like 2* (*CNTNAP2*) predicted to be functionally deleterious and at a highly conserved position. This variant is likely to be extremely rare or private as it was not observed in 942 previously sequenced controls^[@R34]^ or in 1490 other exomes. *CNTNAP2* is directly downregulated by FOXP2^[@R35]^ and has been independently associated with ASD and specific language impairment^[@R34]--[@R37]^. In HEK293T cells, we found that wild-type FOXP1 significantly reduced expression of *CNTNAP2* (p=0.0005), while the truncated protein was associated with a three-fold expression increase (p=0.0056) ([Supplementary Note, Fig. 5d](#SD1){ref-type="supplementary-material"}). Overall, we hypothesize that FOXP1 haploinsufficiency (due to NMD), combined with dysfunction of FOXP1 mutant proteins that escape this process, may yield overexpression of CNTNAP2 proteins, amplifying any deleterious effects of p.H275A in the proband.

Among the \~110 (85 SNVs, 25 indels) novel inherited protein-altering variants in each proband, we identified several rare inherited variants in genes overlapping the SFARI Gene^[@R38]^, a curated database of potential ASD candidate loci, but no excessive burden in cases relative to controls ([Supplementary Table 6](#SD1){ref-type="supplementary-material"}). While the numbers from our pilot study are few, we do observe two cases with a significant *de novo* event and a potential inherited risk variant (12817p1:*FOXP1*/*CNTNAP2* and 12499.p1: *SCN1A*/15q11.2 deletion) highlighting that in some sporadic families a multihit model may be playing a role^[@R3]^ ([Supplementary Table 7](#SD1){ref-type="supplementary-material"}). In the future, this hypothesis could be further explored by comparing burden in a much larger number of affected/unaffected sibling pairs.

The probands with the four potentially causative *de novo* events met strict criteria for a diagnosis of autistic disorder ([Supplementary Note](#SD1){ref-type="supplementary-material"}). Our finding of *de novo* events in genes that have also been disrupted in children with ID without ASD, ID with ASD features, and epilepsy provides further evidence that these genetic pathways may lead to a spectrum of neurodevelopmental outcomes depending on the genetic and environmental context^[@R2],[@R4]^. Recent data suggest that CNVs may also blur these lines with diverse conditions all showing association to the same loci^[@R2],[@R4]^. Distinguishing primary from secondary effects will require a better understanding of the underlying biology and identification of interacting genetic and environmental factors within the phenotypic context of the family. The identification of *de novo* events along with disruptive inherited mutations underlying "sporadic" ASD has the potential to fundamentally transform our understanding of the genetic basis of ASD.
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![Evaluation of *de novo* mutations by simulation, proband severity, and family 12817. **a,b** We compared the mean Grantham (black x-axis) and GERP scores (black y-axis) of the 10 proband *de novo* protein-changing substitutions to 20 HapMap control samples by building a distribution of the mean values of 10 randomly selected common or private variants over 1000 trials. Splice-site and nonsense events were given a maximum Grantham score (215) and indels were not included in the simulation. Histograms show the relative frequency (blue axes) of each distribution. Points show the proband variants, with variants from the same individual highlighted (blue=13708.p1, red=12499.p1). Proband mean values, GERP: 4.349 and Grantham: 104.3. \**FOXP1* not included in proband mean values. **a,** Control common variants (GERP: p\<0.001, Grantham: p=0.015). **b,** Control rare variants (GERP: p=0.026, Grantham: p=0.098). **c,d** We evaluated the disease severity of the mutation carriers 12817.p1-*FOXP1* (brown), 12681.p1-*GRIN2B* (green), 12499-*SCN1A* (blue) and 11666.p1-*LAMC3* (red). **c,** Box and whisker plot of Full Scale Intelligence Quotient (FSIQ) values. **d,** Box and whisker plot of Calibrated Severity Scores (CSS) based on the Autism Diagnostic Observation Schedule (ADOS). Data were available for 19/20 probands; CSS were estimated for two probands based on ADOS module 4 data. **e,** Pedigree for 12817 showing chromatogram traces surrounding *FOXP1* (top) and *CNTNAP2* (bottom) mutation events. Proband carries a *de novo* single-base (+A relative to mRNA) frameshifting mutation p.A339SfsX4 in *FOXP1* and an inherited missense variant p.H275A in *CNTNAP2*.](nihms290937f1){#F1}

###### 

Summary of the exome sequencing results from of 20 sporadic ASD probands

  Family SSC/SAGE ID[\#](#TFN5){ref-type="table-fn"}   Proband Sex   Fa Age months   Mo Age months   Trio Bases[‡](#TFN2){ref-type="table-fn"}   \% target +/− 2 bp   Coding SNV (− dbSNP/1kG)   Rare Disruptive SNV[□](#TFN4){ref-type="table-fn"}   Coding Indels (− dbSNP/1kG)   Rare Indels ≠‚3n   Protein Coding *De Novo* Events
  ---------------------------------------------------- ------------- --------------- --------------- ------------------------------------------- -------------------- -------------------------- ---------------------------------------------------- ----------------------------- ------------------ ---------------------------------
  11048                                                M             358             358             23,901,726                                  88.19                14,095 (752)               131                                                  74 (44)                       27                 **0**
  11307                                                M             421             407             23,549,536                                  86.89                13,509 (583)               75                                                   64 (40)                       19                 **0**
  11580                                                M             443             305             23,823,712                                  87.90                13,912 (642)               89                                                   62 (36)                       24                 **1**
  11666                                                M             398             370             24,179,474                                  89.21                14,306 (622)               77                                                   59 (40)                       25                 **1**
  12325                                                M             363             313             24,088,772                                  88.88                13,866 (629)               79                                                   65 (43)                       24                 **1**
  12499                                                M             425             372             25,217,651                                  93.04                14,479 (634)               86                                                   80 (47)                       21                 **3**
  12575                                                M             351             317             24,259,870                                  89.51                14,568 (679)               78                                                   80 (55)                       26                 **0**
  12647                                                M             541             413             24,669,129                                  91.02                14,144 (830)               78                                                   68 (42)                       22                 **1**
  12680                                                M             502             471             24,437,989                                  90.16                14,124 (642)               69                                                   70 (42)                       24                 **2**
  12681                                                F             399             375             24,723,806                                  91.22                14,750 (691)               93                                                   68 (39)                       20                 **2**
  12817                                                M             485             430             24,520,475                                  90.47                14,364 (656)               83                                                   72 (38)                       24                 **2**
  12974                                                M             366             365             24,235,164                                  89.42                13,990 (555)               52                                                   54 (37)                       23                 **0**
  13095                                                M             337             322             24,460,239                                  90.25                14,605 (645)               66                                                   89 (54)                       29                 **0**
  13253                                                M             436             427             24,070,345                                  88.81                13,775 (610)               96                                                   41 (25)                       16                 **2**
  13284[\*](#TFN3){ref-type="table-fn"}                M             300             302             24,911,060                                  91.91                17,806 (639)               111                                                  151 (79)                      53                 **1**
  13466                                                M             353             385             24,676,574                                  91.05                14,023 (591)               72                                                   58 (39)                       23                 **0**
  13683                                                M             470             402             24,139,439                                  89.06                14,419 (725)               73                                                   72 (49)                       22                 **0**
  13708                                                M             397             382             23,933,169                                  88.30                13,997 (686)               77                                                   78 (41)                       26                 **2**
  13970                                                M             313             234             24,465,009                                  90.26                14,293 (626)               84                                                   89 (58)                       31                 **0**
  SAGE4022                                             F             271             283             24,130,743                                  89.03                14,538 (713)               141                                                  86 (56)                       29                 **0**
  **AVG**                                              18M:2F        397             362             24,319,694                                  89.73                14,378 (658)               86                                                   74 (45)                       25                 0.9

Paternal and maternal ages at time of conception were estimated based on month-year birth information assuming a 9-month pregnancy

Number of bases covered at 8x and Q30 in all three individuals

13284 Included Additional RefSeq Targets

Not observed in 1490 other exomes sequenced at the University of Washington

Simons Simplex Collection (SSC) or Study of Autism Genetics Exploration (SAGE) family number

###### 

Summary of confirmed *de novo* mutation events

  SNV Proband   Type         Chromosome: Position   Gene Symbol                              Variant   AA Change   GERP Score                            Grantham Score                        PolyPhen-2          CpG   Ts/TV   Mut Origin
  ------------- ------------ ---------------------- ---------------------------------------- --------- ----------- ------------------------------------- ------------------------------------- ------------------- ----- ------- ------------
  11580.p1      missense     chr20:2239665          TGM3                                     R         V144I       5.15                                  29                                    probably damaging   Y     Ts      Mo
  11666.p1      missense     chr9:132904111         LAMC3[\*](#TFN6){ref-type="table-fn"}    R         D339G       4.92                                  94                                    probably damaging   N     Ts      Fa
  12325.p1      3′UTR        chr12:55708658         MYO1A                                    R                     2.23                                                                                            N     Ts      
  12325.p1      missense     chr16:19951169         GPR139                                   Y         S151G       1.71                                  56                                    benign              N     Ts      
  12499.p1      missense     chr2:166556317         SCN1A[\*](#TFN6){ref-type="table-fn"}    R         P1894L      5.55                                  98                                    probably damaging   N     Ts      Fa
  12499.p1      synonymous   chr3:38033207          PLCD1                                    K                     −8.24                                                                                           Y     Tv      
  12499.p1      missense     chr6:152865504         SYNE1                                    Y         Y282C       4.48                                  194                                   probably damaging   N     Ts      
  12575.p1      3′UTR        chr9:32619906          TAF1L                                    R                     −1.02                                                                                           Y     Ts      
  12647.p1      3′UTR        chr16:23585994         DCTN5                                    Y                     −0.989                                                                                          N     Ts      
  12647.p1      missense     chr5:68453390          SLC30A5                                  S         S561R       4.6                                   110                                   possibly damaging   N     Tv      
  12680.p1      synonymous   chr2:101992478         IL1R2                                    Y                     −1.53                                                                                           N     Ts      
  12680.p1      synonymous   chr5:132251451         AFF4                                     Y                     −11.2                                                                                           Y     Ts      Fa
  12681.p1      3′ splice    chr12:13614220         GRIN2B[\*](#TFN6){ref-type="table-fn"}   Y                     4.17                                  215[\#](#TFN7){ref-type="table-fn"}                       N     Ts      Fa
  12681.p1      synonymous   chr7:142274902         EPHB6                                    Y                     −3.14                                                                                           Y     Ts      Fa
  12817.p1      synonymous   chr2:143724639         ARHGAP15                                 R                     3.51                                                                                            N     Ts      
  13253.p1      missense     chr3:39204494          XIRP1                                    Y         V483M       2.04                                  21                                    probably damaging   N     Ts      
  13253.p1      synonymous   chr16:74121475         CHST5                                    Y                     −3.22                                                                                           Y     Ts      
  13284.p1      synonymous   chr2:179145956         TTN                                      Y                     0.328                                                                                           Y     Ts      
  13708.p1      missense     chr17:58033198         TLK2                                     Y         S595L       5.43                                  145                                   probably damaging   Y     Ts      
  13708.p1      missense     chr3:30004687          RBMS3                                    Y         T383M       5.44                                  81                                    probably damaging   Y     Ts      
  **Indel**                                                                                                                                                                                                                      
  12817.p1      frameshift   chr3:71132860          FOXP1[\*](#TFN6){ref-type="table-fn"}    +T        A339SfsX4   5.38[‡](#TFN8){ref-type="table-fn"}   215[\#](#TFN7){ref-type="table-fn"}                       NA    NA      Fa

Disruptive *de novo* mutations that are potentially causative

Maximum Grantham score given for splice and frameshifting variants

Average GERP score for two sites flanking the insertion
